Celgene in $450m deal to commercialise MedImmune's anti-PD-L1 candidate
AstraZeneca has inked a development and commercialisation deal with Celgene for its haematology programmed cell death ligand 1 (PD-L1) candidate, MEDI4736.
Archives for April 27, 2015
Mylan rejects $40bn bid, questions Teva’s credibility
Mylan has rejected an unsolicited bid by Teva and upped its offer for Perrigo, as the ongoing saga in the generics space continues.
WHO: Pharmas should give cash not drugs to aid Nepal earthquake relief efforts
Drug companies that want to support aid efforts in Nepal should donate cash rather than medicines according to the World Health Organisation (WHO).
News from CPhI Japan
Sakigake: New Japanese drug laws will foster global innovation says MHLW
‘Epoch making’ revisions to Japanese drug laws have provided a pathway for development of safer, more innovative drugs according to MHLW director, Haruo Akagawa.
LabCorp sees Q1 revenue rise slightly as Covance growth downgraded for FY15
Just two months after Covance shareholders signed off on LabCorp acquiring the company, and all seems to be going according to plan, though financial expectations for the rest of the year were slightly lowered by the diagnostics company.
CNS, oncology, complex trials boost INC Research’s Q1 growth
CRO INC Research saw its net service revenue increase by 14.5% to $211.5m in Q1, which was considerably higher than analyst expectations and driven by particularly strong growth in trials around CNS (central nervous system), oncology and other complex...
Is there a CRO bubble? Analysts say yes, with caveats
With sky-high valuations and soaring M&A prices, the question of whether there’s a biotech bubble continues to crop up, though now some analysts are saying this so-called bubble and its inevitable pop may be a cause for concern for CROs (contract...
Allergan and Hospira recalls
Hospira has recalled one lot of the anaesthetic Bupivacaine after a customer discovered orange and black particles floating and embedded in a glass vial.
Icon CEO addresses Pfizer situation following addition of 3rd CRO partner
Nearly a week since Pfizer formally announced its third CRO partner as PPD, the spotlight shifted to Icon as the CRO earns nearly one-third of its revenue from Pfizer.